Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Merck & Co., Inc. | 1.21M | $3.0M | 0.29% | -- | 2026-06-30 |
| Ikarian Capital, LLC | 74.7K | -- | 0.02% | -- | 2026-06-30 |
| Citadel Advisors LLC | 36.6K | -- | 0.01% | +18.8K | 2026-06-30 |
| Renaissance Technologies LLC | 33.8K | -- | 0.01% | -5.4K | 2026-06-30 |
| Annis Gardner Whiting Capital Advisors, LLC | 30.0K | -- | 0.01% | -- | 2026-06-30 |
| J. Safra Sarasin Holding AG | 22.9K | -- | 0.01% | -- | 2026-06-30 |
| Rhumbline Advisers | 21.8K | -- | 0.01% | +190 | 2026-06-30 |
| Jane Street Group, LLC | 20.6K | -- | 0.00% | -- | 2026-06-30 |
| Boothbay Fund Management, LLC | 18.4K | -- | 0.00% | -- | 2026-06-30 |
| Stonepine Capital Management, LLC | 17.6K | -- | 0.00% | -2.2K | 2026-06-30 |
